China Pharmaceutical Industry Information Center (CMIC) sponsored the opening of the National Medicinal Industry Information Annual Meeting in Shanghai in 2018. The meeting solemnly released the list of the top 100 enterprises in China's pharmaceutical industry in 2017, which attracted the attention of the industry. Disha Pharmaceutical Industry was once again ranked the top 100 enterprises in China's pharmaceutical industry for eight consecutive years.
According to the statistics and analysis of the China Pharmaceutical Industry Information Center, the enterprises listed on the Top 100 list in 2017 continued their strong growth momentum, breaking through 750 billion yuan mark with the growth rate of 10.2% of the main business income. Although the growth rate decreased by 0.9 percentage points compared with the same period last year, the growth trend remained basically stable. It is worth noting that the top 100 threshold also increased from 2 billion 440 million yuan last year to 2 billion 560 million yuan, a slight increase of 5%. Under the leading role of top 100 enterprises, the pharmaceutical industry is gradually moving towards scale economy.
Disha Pharmaceutical Co., Ltd. was founded in 1993. It is located in Weihai, an ecologically livable city with a global reputation. The group is a national key high-tech enterprise which integrates production, learning and research, science, industry and trade. After more than 20 years of development, it has formed three major business sectors: preparations, green high-tech raw materials, marine biological health industry, and has built five major students: western medicine preparations, raw materials, traditional Chinese medicine, new marine biological materials and marine biological health products. Production base. In 2017, the sales revenue reached 3 billion 600 million yuan and was selected into top 100 enterprises in China's pharmaceutical industry for 8 consecutive years.